Clinical Practice Guidelines: Toxicology and toxinology/ Approach to the poisoned patient

<table>
<thead>
<tr>
<th>Policy code</th>
<th>CPG_TO_AHP_0221</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>February, 2021</td>
</tr>
<tr>
<td>Purpose</td>
<td>To ensure a consistent approach to the management of the poisoned patient.</td>
</tr>
<tr>
<td>Scope</td>
<td>Applies to Queensland Ambulance Service (QAS) clinical staff.</td>
</tr>
<tr>
<td>Health care setting</td>
<td>Pre-hospital assessment and treatment.</td>
</tr>
<tr>
<td>Population</td>
<td>Applies to all ages unless stated otherwise.</td>
</tr>
<tr>
<td>Source of funding</td>
<td>Internal – 100%</td>
</tr>
<tr>
<td>Author</td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td>Review date</td>
<td>February, 2024</td>
</tr>
</tbody>
</table>

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by appropriately qualified QAS clinicians when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.


This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en

For copyright permissions beyond the scope of this license please contact: Clinical.Guidelines@ambulance.qld.gov.au
Acute poisoning can occur from unintentional or deliberate exposure. The initial management priorities for the poisoned patient follow usual QAS guidelines for resuscitation and standard cares. In addition, clinicians should perform a structured risk assessment to help determine ongoing treatment requirements specific to the agent involved. Decontamination may be necessary for certain toxins. The vast majority of poisoning cases require regular patient observations and support of airway, breathing and circulation. Clinicians must be vigilant in ensuring appropriate PPE is worn while managing potentially poisoned patients.

### Clinical features

- Classic constellations of clinical features or ‘toxidromes’ are associated with specific toxic ingestions and can guide further management.

<table>
<thead>
<tr>
<th>Toxidrome</th>
<th>Examples of agents</th>
<th>Clinical signs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholinergic toxicity</td>
<td>• Organophosphates • Carbamates • Nicotine • Muscarinic • Mushrooms</td>
<td>• Constricted pupils • Sweating • Salivation • Bronchorrhoea • Lacrimation • Bradycardia • Agitation • Fasciculations • Coma • Seizures</td>
</tr>
<tr>
<td>Anticholinergic toxicity</td>
<td>• Antihistamines • Quetiapine • Olanzapine • Benztoprine • Atropine • Plants (e.g. Datura)</td>
<td>• Dilated pupils • Hyperthermia • Agitation • Tachycardia • Dry mouth • Flushed dry skin</td>
</tr>
<tr>
<td>Opioid toxicity</td>
<td>• Heroin • Oxycodone • Methadone • Morphine • Fentanyl</td>
<td>• Constricted pupils • Respiratory depression • Sedation • Coma</td>
</tr>
<tr>
<td>Serotonin toxicity</td>
<td>• SSRI • SNRI • MAOI • Methamphetamine • MDMA</td>
<td>• Dilated pupils • Tremor • Hyperreflexia • Clonus • Hyperthermia • Agitation</td>
</tr>
<tr>
<td>Sympathomimetic toxicity</td>
<td>• Methamphetamine • MDMA • Cocaine • Methylphenidate</td>
<td>• Dilated pupils • Tachycardia • Sweating • Hyperthermia • Agitation</td>
</tr>
</tbody>
</table>
Risk assessment

A thorough risk assessment is crucial and can predict the expected clinical course of the exposure. Gathering empty pill packets and gaining collateral history from friends and family is especially useful and should always be performed when possible, to aid on risk assessment. The clinician should aim as quickly as possible to determine:

- Agent/s ingested
- Dose/s
- Timing of ingestion or exposure
- Any symptoms or signs which have developed
- Important patient factors (e.g. pre-existing coronary heart disease)

This information can be crucial in guiding ongoing management of the patient.

An Emergency Examination Authority (EEA) is necessary if the patient is deemed to be at an imminent risk of harm to self or others.

Additional information

- Positive identification of the type and/or quantity of overdose agent can be extremely useful for determining the most appropriate patient management plan and antidote if appropriate.
- Call the Poisons Information Centre Hotline: 13 11 26 if there are any concerns regarding the patient’s presentation and more specific information is required.
- Standard PPE is all that is required for the vast majority of toxic exposures.
- Unintentional paediatric ingestions rarely involve more than a few tablets or a mouthful of poison. However, potentially lethal paediatric ingestions\(^2\) where all suspected exposures should be transported to hospital include:
  - Antiarrhythmics (e.g. calcium channel blockers, propranolol)
  - Anticonvulsants (e.g. lamotrigine, gabapentin)
  - Chloroquine/Hydroxychloroquine
  - Essential oils, especially eucalyptus oil
  - Gamma-hydroxybuturane (GHB)
  - Hydrocarbons
  - Opioids (e.g. methadone)
  - Organophosphates
  - Paraquat
  - Stimulants (e.g. methamphetamine, MDMA)
  - Sulfonylureas (e.g. glibenclamide, gliclazide, glimepiride, glipizide)
  - Theophylline
  - Toxic alcohols
  - Tricyclic antidepressants (TCAs)

Additional information (cont.)

- If the packaging of the suspected patient poisoning/overdose agent is able to be acquired at the scene (e.g. medication packets, poison container, etc), these must be placed in a sealable bag and taken to the hospital with the patient if it is safe to do so without risking contamination to self and others.
Additional information (cont.)

- Patient in cardiac arrest secondary to toxicology/toxinology causes may benefit from extended resuscitation times and/or additional clinical interventions. All toxicology/toxinology patients (excluding narcotic overdoses) in cardiac arrest must be discussed with the QAS medical officer via the QAS Clinical Consultation and Advice Line prior to ceasing resuscitation efforts.

PROVIDE SPECIFIC MANAGEMENT FOR KNOWN TOXIDROME / INGESTION
Treat according to clinical situation prioritising:
- Airway management
- Respiratory support
- Circulation support

Consider:
- Consult Poisons Information Ph: 131126
- 12-Lead ECG
- IV access
- Antiemetic
- Antidote
- Oxygen
- Sedation
- IPPV
- EEA

Note: Clinicians must only perform procedures for which they have received specific training and authorisation by the QAS.

Transport to hospital
Pre-notify as appropriate